|The p53-HAT connection: PCAF rules?|
|Jump to Full Text|
|PMID: 22889733 Owner: NLM Status: MEDLINE|
|Oleg Laptenko; Carol Prives|
Related Documents :
|9048133 - Activation and proliferation of lymphocytes and other mammalian cells in microgravity.
14681423 - Scmd: saccharomyces cerevisiae morphological database.
2133463 - Feasibility of the immunohistochemical detection of endogenous steroids in paraffin-emb...
|Type: Comment; News Date: 2012-08-14|
|Title: Cell cycle (Georgetown, Tex.) Volume: 11 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2012 Aug|
|Created Date: 2012-08-28 Completed Date: 2013-02-04 Revised Date: 2014-03-19|
Medline Journal Info:
|Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States|
|Languages: eng Pagination: 2975-6 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Cyclin-Dependent Kinase Inhibitor p21
Histones / metabolism*
p300-CBP Transcription Factors / metabolism*
|R01 CA077742/CA/NCI NIH HHS|
|0/Cyclin-Dependent Kinase Inhibitor p21; 0/Histones; EC 22.214.171.124/p300-CBP Transcription Factors|
|Cell Cycle. 2012 Jul 1;11(13):2458-66
Journal ID (nlm-ta): Cell Cycle
Journal ID (iso-abbrev): Cell Cycle
Journal ID (publisher-id): CC
Publisher: Landes Bioscience
Copyright © 2012 Landes Bioscience
Print publication date: Day: 15 Month: 8 Year: 2012
pmc-release publication date: Day: 15 Month: 8 Year: 2012
Volume: 11 Issue: 16
First Page: 2975 Last Page: 2975
PubMed Id: 22889733
Publisher Id: 2012NV0745
Publisher Item Identifier: 21528
|The p53-HAT connection : PCAF rules?|
|Department of Biological Sciences; Columbia University; New York, NY USA
|*Correspondence to: Carol Prives, Email: email@example.com
Multiple structural, biochemical and in vivo studies have solidified the role that histone acetyltransferases (HATs) play in regulation of the p53 pathway.1 HATs are known to modulate p53 functions in many ways: from regulating its stability to promoting acetylation-dependent interactions with DNA as well as various co-factors and chromatin modifiers.1 Of these, p300, CBP, PCAF and Tip60 are the most well-studied p53 co-factors that can regulate (sometimes selectively) a number of bona fide p53 targets involved in cell cycle, apoptosis, DNA repair, metabolism and other processes.2 Of particular current interest is the time- and stress-dependent interplay between different acetyltransferases. Yet, though we now know the players, we still have only limited knowledge of their performances.
A paper by Love et al. in a previous issue of Cell Cycle, has contributed new insight into the function of one such HAT.3 Using multiple p53-activating stress conditions in combination with siRNA-mediated knockdown of specific HATs in several cancer cell lines, the authors have demonstrated the dependence of p21-driven cell cycle arrest on the histone acetyl transferase activity of PCAF. They found that PCAF, but not p300 or CBP (two closely related and well characterized transcriptional co-activators) is absolutely required for maximal p21 expression in several settings. Intriguingly, their work indicates that PCAF is exclusively important for the activation of cell cycle arrest through p53- but not Rb-dependent pathways. A pictorial description of possible events leading to p21 activation is shown in Figure 1.
Key features of the paper by Love et al. are summarized as follows. First, PCAF-dependent effects on p21 transcription are apparently unrelated to its reported MDM2-directed E3 ligase activity, which otherwise would result in subsequent elevation of p53 levels.4 Second, acetylation of a previously identified PCAF site within p53, Lys320,5 is not necessary for p21 transactivation, although the acetyl-transferase activity of PCAF, per se, is indispensable. Accordingly, previously identified PCAF sites within the H3 core histone, Lys9 and Lys14, are markedly acetylated at the strong p53 “distal” binding site within the p21 promoter following stress-induced p53 activation. Since the same lysine residues are known to be acetylated by other HATs (e.g., GCN5, SRC-1 and GCN5, p300, Tip60 and SRC-1), stress- or co-factor-dependent specificity of those modifications would need to be investigated in future studies. Finally, somewhat unexpectedly, the authors did not observe any significant changes in the levels of PCAF at the distal p53 binding site within the p21 promoter before and after p53 activation. So, it is unclear what brings PCAF to the promoter of p21 gene. Detailed analysis of the nucleosome content at that region, as reported by Laptenko et al.,6 could be informative in that regard.
Unlike the p300 and CBP HATs, human PCAF functions within a complex of more than 20 proteins.7 The acetyltransferase activity of the PCAF complex toward nucleosomal substrates is known to be markedly higher than of the PCAF enzyme itself. Several subunits within the complex show 100% identity to TAFs (TATA-binding protein-associated factors), while others are highly homologous but not identical to them. One such subunit, TAFII31 (a part of the TFIID complex), has already been shown to stabilize and activate p538; so this may provide some connection between p53-PCAF-dependent events at the distal p53 sites and the region of the promoter that is close to the start site. Finally, the largest subunit of the PCAF complex, TRAPP/PAF400, a member of the ATM super family and a component of the Tip60 HAT complex, may facilitate multiprotein assemblies (e.g., chromatin remodeling complexes) on targeted promoters .
A good scientific study, in its attempt to answer a few specific questions, inevitably generates more questions. Among those prompted by the report by Love et al. are: what brings PCAF to the p21 promoter in the absence of high levels of p53? What other subunits/activities, if any, of the PCAF complex are vital for p21 promoter activation? What PCAF-dependent changes in chromatin occur within the p21 transcription start site following stress? Future experiments will hopefully be able to address these and other questions.
Previously published online: www.landesbioscience.com/journals/cc/article/21528
|1.||Brooks CL,et al. Protein CellYear: 201124566210.1007/s13238-011-1063-921748595|
|2.||Vousden KH,et al. CellYear: 20091374133110.1016/j.cell.2009.04.03719410540|
|3.||Love IM,et al. Cell CycleYear: 20121124586610.4161/cc.2086422713239|
|4.||Linares LK,et al. Nat Cell BiolYear: 20079331810.1038/ncb154517293853|
|5.||Sakaguchi K,et al. Genes DevYear: 19981228314110.1101/gad.12.18.28319744860|
|6.||Laptenko O. Proc Natl Acad Sci USAYear: 2011108103859010.1073/pnas.110568010821606339|
|7.||Schiltz RL,et al. Biochim Biophys ActaYear: 20001470M375310722926|
|8.||Lu H,et al. Proc Natl Acad Sci USAYear: 1995925154810.1073/pnas.92.11.51547761466|
Previous Document: Molecular basis of the functional distinction between Cln1 and Cln2 cyclins.
Next Document: Centerline tracking for quantification of reverse structural remodeling of the pulmonary veins follo...